← Sanofi

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $34.7b
$36.2b +4.31%
$35.7b -1.46%
$37.6b +5.48%
$37.4b -0.70%
$39.2b +4.83%
$45.4b +15.86%
$46.4b +2.32%
$44.3b -4.65%
$46.7b +5.49%
$48.9b +4.72%
Other revenues — $1.1b $1.2b $1.5b $1.3b $1.4b $2.4b $3.4b $3.2b $3.1b —
Cost of Goods and Services Sold $10.7b
$11.6b +8.49%
$11.4b -1.52%
$12.0b +4.73%
$12.2b +1.51%
$12.3b +0.81%
$13.7b +11.75%
$14.2b +3.95%
$13.2b -7.24%
$13.0b -1.18%
$13.3b +2.10%
Cost of sales ($10.7b)
($11.6b) -8.52%
($11.4b) +1.53%
($12.0b) -4.73%
($12.2b) -1.51%
($12.3b) -0.81%
($13.7b) -11.75%
($14.2b) -3.95%
($13.2b) +7.24%
($13.0b) +1.18%
$13.3b +202.10%
Gross Profit $24.0b
$24.6b +2.45%
$24.2b -1.43%
$25.7b +5.83%
$25.2b -1.73%
$26.9b +6.77%
$31.7b +17.73%
$32.2b +1.62%
$31.1b -3.50%
$33.7b +8.32%
$35.6b +5.73%
Research and development $5.2b $5.5b $5.9b $6.0b $5.5b $5.7b $6.7b $6.7b $7.4b $7.8b $8.1b
Selling, General and Administrative Expense $9.5b $10.1b $9.9b $9.9b $9.4b $9.6b $10.5b $10.7b $9.2b $9.5b $10.5b
Amortization of intangible assets — ($1.9b) ($2.2b) ($2.1b) ($1.7b) ($1.6b) ($2.1b) ($2.2b) ($1.7b) ($1.8b) —
Restructuring costs and similar items — ($731.0m) ($1.5b) ($1.1b) ($1.1b) ($820.0m) ($1.3b) ($1.5b) ($1.4b) ($1.1b) —
Operating expenses:
Other operating expenses ($11.0m) ($233.0m) ($548.0m) ($1.2b) ($1.4b) ($1.8b) ($2.5b) ($3.5b) ($4.4b) ($5.7b) —
Other Operating Income Expense $6.5b $5.8b $4.7b ($633.0m) ($926.0m) ($1.4b) ($1.2b) ($3.0b) ($3.8b) ($4.9b) —
Interest Expense On Lease Liabilities — — — $39.0m $38.0m $35.0m $40.0m $39.0m $42.0m $45.0m $730.0m
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method $136.0m $85.0m $499.0m $255.0m $359.0m $39.0m $68.0m ($115.0m) $60.0m ($155.0m) —
Share of profit/(loss) from investments accounted for using the equity method $136.0m $85.0m $499.0m $255.0m $359.0m $39.0m $68.0m ($115.0m) $60.0m ($155.0m) —
Income before tax and investments accounted for using the equity method $5.7b $5.5b $4.4b $2.8b $13.8b $7.8b $10.4b $7.2b $6.7b $6.2b $5.4b
Current Tax Expense (Income) $1.9b $2.6b $1.2b $1.9b $1.9b $1.9b $2.8b $2.6b $2.2b $3.4b —
Deferred Tax Expense (Income) ($543.0m) ($909.0m) ($731.0m) ($1.8b) ($99.0m) ($350.0m) ($768.0m) ($958.0m) ($948.0m) ($2.4b) —
Income Tax Expense Continuing Operations $1.3b $1.7b $481.0m $139.0m $1.8b $1.6b $2.0b $1.6b $1.2b $1.0b $1.2b
Net income from continuing operations — $3.9b $4.4b $2.9b $12.3b $6.3b $8.1b $5.1b $5.6b $5.0b —
Net income excluding the exchanged/held-for-exchange Animal Health business $314.0m $4.6b ($13.0m) ($101.0m) $0 $0 $401.0m $338.0m $64.0m $2.9b —
Net income $4.8b
$8.5b +77.85%
$4.4b -48.34%
$2.8b -35.67%
$12.3b +335.32%
$6.3b -49.16%
$8.5b +35.12%
$5.4b -35.93%
$5.6b +3.35%
$7.9b +39.75%
$4.0b -49.59%
Net income attributable to non-controlling interests $91.0m $121.0m $104.0m $31.0m $36.0m $56.0m $113.0m $36.0m $58.0m $38.0m —
Net income attributable to equity holders of Sanofi $4.7b $8.4b $4.3b $2.8b $12.3b $6.2b $8.4b $5.4b $5.6b $7.8b —
Basic Earnings (Loss) Per Share $3.66 $6.71 $3.45 $2.24 $9.82 $4.97 $6.69 $4.31 $4.44 $6.40 $1.65
Diluted Earnings (Loss) Per Share $3.63 $6.66 $3.43 $2.23 $9.77 $4.95 $6.66 $4.30 $4.43 $6.37 $1.64
Basic earnings (loss) per share from discontinued operations — — — — — — $0.31 $0.25 $0.04 $2.35 $1.65
Diluted earnings (loss) per share from discontinued operations — — — — — — $0.31 $0.25 $0.04 $2.34 $1.64
Average number of shares after dilution (in shares) — 1.3b 1.3b 1.3b 1.3b 1.3b 1.3b 1.3b 1.3b 1.2b —
Average number of shares outstanding (in shares) — 1.3b 1.2b 1.2b 1.3b 1.3b 1.3b 1.3b 1.3b 1.2b —
Additional Financial Items
Applicable Tax Rate $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 —
Average Effective Tax Rate $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 —
Employee Benefits Expense $9.1b $9.3b $9.3b $9.1b $9.1b $9.3b $10.0b $9.8b $10.2b $9.8b —
Expense From Share-Based Payment Transactions With Employees $250.0m $258.0m $282.0m $252.0m $274.0m $244.0m $245.0m — — — —
Finance Costs $924.0m $420.0m $435.0m $444.0m $390.0m $368.0m $440.0m $1.3b $1.1b $563.0m —
Finance Income $68.0m $147.0m $164.0m $141.0m $53.0m $40.0m $206.0m $591.0m $519.0m $394.0m —
Impairment Loss Recognised In Profit Or Loss Goodwill — $0 $0 $0 $0 $0 $0 $0 $0 $0 —
Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill — — — — — $192.0m ($454.0m) $896.0m $248.0m $2.2b —
Other Employee Expense $224.0m $219.0m $225.0m $229.0m $261.0m $269.0m $267.0m $531.0m $766.0m $736.0m —
Postemployment Benefit Expense Defined Benefit Plans $273.0m $275.0m $261.0m $119.0m $159.0m $273.0m $236.0m — — — —
Profit Loss Attributable To Noncontrolling Interests $91.0m $121.0m $104.0m $31.0m $36.0m $56.0m $113.0m $36.0m $58.0m $38.0m —
Profit Loss Attributable To Owners Of Parent $4.7b $8.4b $4.3b $2.8b $12.3b $6.2b $8.4b $5.4b $5.6b $7.8b —
Profit Loss From Operating Activities $6.5b $5.8b $4.7b $3.1b $14.1b $8.1b $10.7b $7.9b $7.3b $6.3b —
Tax Rate Effect Of Foreign Tax Rates ($0) ($0) ($0) ($0) ($0) ($0) ($0) ($0) ($0) ($0) —
Selling and general expenses ($9.5b) ($10.1b) ($9.9b) ($9.9b) ($9.4b) ($9.6b) ($10.5b) ($10.7b) ($9.2b) ($9.5b) —
Impairment of intangible assets — ($293.0m) ($718.0m) ($3.6b) ($330.0m) ($192.0m) $454.0m ($896.0m) ($248.0m) ($2.2b) —
Fair value remeasurement of contingent consideration — ($159.0m) $117.0m $238.0m $124.0m ($4.0m) $27.0m ($93.0m) ($96.0m) ($104.0m) —
Other gains and losses, and litigation — ($215.0m) $502.0m $327.0m $136.0m ($5.0m) ($370.0m) ($38.0m) ($470.0m) ($255.0m) —
Financial expenses — ($420.0m) ($435.0m) ($444.0m) ($390.0m) ($368.0m) ($440.0m) ($1.3b) ($1.1b) ($563.0m) —
Financial income $68.0m $147.0m $164.0m $141.0m $53.0m $40.0m $206.0m $591.0m $519.0m $394.0m —

Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.